cladribine has been researched along with Cancer, Second Primary in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (27.91) | 18.2507 |
| 2000's | 21 (48.84) | 29.6817 |
| 2010's | 10 (23.26) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cornet, E; Maitre, E; Troussard, X | 1 |
| Abughanimeh, O; Bahaj, W; Foxworth, J; Gaur, R; Qasrawi, A; Qasrawi, L | 1 |
| Amarante, GD; Buccheri, V; da Rosa, LI; da Silva, WF; de Siqueira, IA; Neto, AC; Rego, EM; Rocha, V; Velloso, EDRP | 1 |
| Bogdanovic, A; Colovic, N; Gotic, M; Kraguljac-Kurtovic, N; Marisavljevic, D | 1 |
| Blonski, JZ; Boguradzki, P; Calbecka, M; Dmoszynska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Jamroziak, K; Kloczko, J; Kowal, M; Kuliczkowski, K; Lech-Maranda, E; Moskwa, A; Piotrowska, M; Piszcz, J; Potoczek, S; Robak, T; Skotnicki, AB; Stella-Holowiecka, B; Sulek, K; Warzocha, K; Zawilska, K | 1 |
| Burian, C; Rosenberg, JD; Saven, A; Waalen, J | 1 |
| Beyan, C; Kaptan, K | 1 |
| Barshack, I; Feldberg, E; Filanovsky, K; Shvidel, L; Ustaev, E; Vorst, E; Yacobi, R | 1 |
| Inagaki, H; Iwashima, Y; Kusumoto, S; Kutsuna, T; Maeno, K; Miyazaki, M; Nakamura, A; Nakao, M; Oguri, T; Ota, C; Ozasa, H; Sato, S; Takakuwa, O; Ueda, R; Uemura, T | 1 |
| Alexandrescu, DT; Dasanu, CA | 1 |
| Setoodeh, R; Zhang, L | 1 |
| Baudo, F; deCataldo, F | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Pralle, H; Schmidt-Wolf, I; Strehl, J; Ziske, C | 1 |
| Burian, C; Goodman, GR; Koziol, JA; Saven, A | 1 |
| Bartkowiak, J; Kordek, R; Korycka, A; Robak, T; Smolewski, P; Szmigielska-Kapłon, A; Wawrzyniak, E | 1 |
| Golf, A; Haferlach, T; Hiddemann, W; Lenz, G; Rüdiger, T | 1 |
| Blonski, JZ; Całbecka, M; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, A; Gora-Tybor, J; Hellmann, A; Kasznicki, M; Komarnicki, M; Konopka, L; Lewandowski, K; Moskwa, A; Robak, T; Sokołowska, B; Sułek, K; Tomaszewska, A | 1 |
| André, M; Costantini, S; Ferrant, A; Francart, J; Lambert, C; Layios, N; Michaux, L; Robert, A; Sonet, A; Van Den Neste, E | 1 |
| Bartl, R; Dietzfelbinger, H; Haferlach, T; Heinemann, V; Jehn, U | 1 |
| Barbashina, V; Bhargava, R; Filippa, DA; Teruya-Feldstein, J | 1 |
| Gupta, M; Hassan, R; Kern, W; Ozer, H | 1 |
| Chou, T; Kasai, M; Kobayashi, Y; Matsuno, Y; Miura, I; Mori, S; Morishima, Y; Murayama, T; Nakamura, S; Ogura, M; Ohashi, Y; Sugai, S; Tobinai, K; Uike, N | 1 |
| Robak, T | 1 |
| Chadha, P; Evanchuk, DM; Hakimian, D; Kim, B; Mendiratta, P; Peterson, LC; Rademaker, AW; Tallman, MS | 1 |
| Bila, J; Boskovic, D; Catovsky, D; Cemerikic, V; Elezovic, I; Gotic, M; Grujicic, D; Jocic, DJ; Magic, Z; Pavlovic, D; Stosic, T; Wotherspoon, A | 1 |
| Gratwohl, A; Rimner, T; Tichelli, A; Went, P | 1 |
| Ballabeni, P; Cerny, T; Fey, M; Hess, U; Laurencet, F; Luthi, JM; Plancherel, C; Rufener, B; Zulian, GB | 1 |
| Anderson, WF; Elias, AL; Pankey, LR; Reeves, JE; Robbins, BA | 1 |
| Chan, DW; Chan, TK; Chiu, E; Kwong, YL; Liang, R | 1 |
| Bosly, A; Brousset, P; Delannoy, A; Pris, J; Riga-Huguet, F; Schlaifer, D | 1 |
| Adams, T; Estey, E; Jiang, H; Keating, MJ; Kurzrock, R; O'Brien, S; Strom, SS; Talpaz, M | 1 |
| Gordon, LI; Hakimian, D; Huang, CF; Klein, L; Kong, LR; Kuzel, TM; Tallman, MS; Variakojis, D; Wollins, E; Zanzig, C | 1 |
| Au, WY; Connors, JM; Gallagher, R; Gascoyne, RD; Klasa, RJ; Le, N | 1 |
| Burian, C; Koziol, JA; Piro, LD; Saven, A | 1 |
| Annino, L; Barrett, JA; Cheson, BD; Coiffier, B; Connors, J; Damasio, E; Lauria, F; Montello, MJ; Sorensen, JM; Tallman, M; Vena, DA | 1 |
| Błasińska-Morawiec, M; Błoński, J; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Hansz, J; Hałaburda, K; Hellmann, A; Hołowiecki, J; Konopka, L; Kotlarek-Haus, S; Potoczek, S; Robak, T; Skotnicki, AB; Urasiński, I; Zdziarska, B | 1 |
| Al-Fiar, F; Curtis, J; Lipton, JH; Meharchand, J | 1 |
| Barrett, J; Cheson, BD; Freidlin, B; Vena, DA | 1 |
| Bastie, JN; Castaigne, S; Cazals-Hatem, D; D'Agay, MF; Dabout, D; Daniel, MT; Degos, L; Dombret, H; Flandrin, G; Glaisner, S; Noel-Walter, MP; Poisson, D; Rabian, C | 1 |
| Corbett, WE; Daeninck, PJ; Eisenhauer, E; Johnston, JB; Wainman, N; Zaentz, SD | 1 |
| Seshadri, P | 1 |
| Delannoy, A; Feremans, W; Ferrant, A; Michaux, L; Van Den Neste, E | 1 |
| Bartkowiak, J; Błonski, JZ; Kasznicki, M; Kordek, R; Robak, T; Wawrzyniak, E | 1 |
10 review(s) available for cladribine and Cancer, Second Primary
| Article | Year |
|---|---|
Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment.
Topics: Algorithms; Antimetabolites, Antineoplastic; B-Lymphocytes; Biopsy; Bone Marrow Examination; Cladribine; Humans; Immunophenotyping; Immunotoxins; Leukemia, Hairy Cell; Middle Aged; Mutation, Missense; Neoplasm Proteins; Neoplasms, Second Primary; Neoplastic Stem Cells; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Risk Assessment; Rituximab; Salvage Therapy | 2019 |
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Heart Diseases; Hematologic Diseases; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Liposomes; Meta-Analysis as Topic; Mucositis; Multicenter Studies as Topic; Neoplasms, Second Primary; Remission Induction; Survival Rate; Treatment Outcome | 2019 |
CD56-Positive Acute Myeloid Leukemia Following Treatment of Hairy Cell Leukemia with Cladribine - Report of 2 Cases and Review of the Literature.
Topics: Antineoplastic Agents; CD56 Antigen; Cladribine; Fatal Outcome; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction | 2019 |
Risk of additional cancers in untreated and treated hairy cell leukemia patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Incidence; Leukemia, Hairy Cell; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pentostatin | 2010 |
Secondary T-lymphoblastic leukemia in a patient with hairy cell leukemia following cladribine therapy: report of an extremely rare case and review of the literature.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 9; Cladribine; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Translocation, Genetic | 2012 |
Advances in the treatment of hairy-cell leukaemia.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Cell Adhesion Molecules; Cladribine; Humans; Interferon-alpha; Lectins; Leukemia, Hairy Cell; Neoplasm, Residual; Neoplasms, Second Primary; Pancytopenia; Pentostatin; Receptors, Interleukin-2; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Spleen; Splenectomy; Splenomegaly; Treatment Outcome; Vidarabine | 2003 |
Acute myeloid leukemia following treatment with cladribine for hairy cell leukemia: a case report and review of the literature.
Topics: Acute Disease; Aged; Cladribine; Fatal Outcome; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid; Male; Neoplasms, Second Primary; Pancytopenia | 2004 |
The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms, Second Primary; Poland; Randomized Controlled Trials as Topic | 2005 |
Secondary acute myeloid leukemia 4 years after the diagnosis of hairy cell leukemia: case report and review of the literature.
Topics: Acute Disease; Antineoplastic Agents; Cladribine; Humans; Interferon-alpha; Leukemia, Hairy Cell; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary | 1999 |
Second primary tumors and immune phenomena after fludarabine or 2-chloro-2'-deoxyadenosine treatment.
Topics: Antineoplastic Agents; Autoimmunity; Cladribine; Humans; Immunosuppressive Agents; Neoplasms; Neoplasms, Second Primary; Vidarabine | 2001 |
8 trial(s) available for cladribine and Cancer, Second Primary
| Article | Year |
|---|---|
Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cladribine; Cyclophosphamide; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Mitoxantrone; Neoplasms, Second Primary; Treatment Outcome | 2014 |
High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Female; Humans; Leukopenia; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasms, Second Primary; Opportunistic Infections; Survival Analysis | 2004 |
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
Topics: Adult; Aged; Cladribine; Female; Humans; Japan; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycosis Fungoides; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Recurrence; Remission Induction; Salvage Therapy; Survival Analysis | 2004 |
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Survival Analysis; Time Factors | 2005 |
The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Hematologic Diseases; Humans; Immunocompromised Host; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Prospective Studies; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 2007 |
Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Infections; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Prognosis; Survival Analysis; Treatment Outcome | 1998 |
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Survival Analysis | 1998 |
Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Canada; Cause of Death; Cladribine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Injections, Intravenous; Interferon-alpha; Leukemia, Hairy Cell; Longitudinal Studies; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pentostatin; Remission Induction; Survival Rate; Treatment Outcome | 2000 |
25 other study(ies) available for cladribine and Cancer, Second Primary
| Article | Year |
|---|---|
Outcomes and second neoplasms in hairy cell leukemia: A retrospective cohort.
Topics: Adult; Aged; Aged, 80 and over; Cladribine; Disease-Free Survival; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Retrospective Studies; Rituximab; Splenectomy; Survival Rate | 2019 |
Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Remission Induction; Retreatment; Treatment Outcome; Young Adult | 2014 |
Variant hairy cell leukemia following papillary urothelial neoplasm of bladder.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Cladribine; Flow Cytometry; Genetic Variation; Humans; Immunohistochemistry; Immunophenotyping; Immunosuppressive Agents; Leukemia, Hairy Cell; Male; Neoplasms, Second Primary; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Second hematologic malignancies in hairy cell leukemia: report of two patients with dynamic mutations in the BRAF gene.
Topics: Antigens, CD20; Antineoplastic Agents; Cladribine; DNA Mutational Analysis; Female; Hematologic Neoplasms; Humans; Immunohistochemistry; Leukemia, Hairy Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Mutation; Neoplasms, Second Primary; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins B-raf | 2015 |
Small-cell lung cancer arising after chemotherapy for a patient with lymphoma of pulmonary mucosa-associated lymphoid tissue-a case report.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Cladribine; Etoposide; Fatal Outcome; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Mucous Membrane; Neoplasms, Second Primary; Rituximab; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2009 |
Successful treatment with 2-chlorodeoxyadenosine of secondary lesions of the central nervous system in low-grade lymphoid malignancies.
Topics: Central Nervous System Neoplasms; Cladribine; Disease-Free Survival; Female; Humans; Leukemia, Hairy Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasms, Second Primary; Treatment Outcome; Waldenstrom Macroglobulinemia | 2002 |
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Interferons; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pentostatin; Remission Induction; Splenectomy; Survival Rate; Treatment Outcome | 2003 |
Hodgkin's type of Richter's syndrome in familial chronic lymphocytic leukemia treated with cladribine and cyclophosphamide.
Topics: Abdominal Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cladribine; Cyclophosphamide; Family Health; Herpesvirus 4, Human; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Neoplasms, Second Primary; Syndrome | 2003 |
Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine.
Topics: Antineoplastic Agents; Cladribine; Epstein-Barr Virus Infections; Humans; Leukemia, Hairy Cell; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoplasms, Second Primary | 2003 |
Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Retrospective Studies; Syndrome; Vincristine | 2004 |
An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Cohort Studies; Female; Follow-Up Studies; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Second Primary; Palliative Care; Pentostatin; Splenectomy; Survival Rate; Treatment Outcome | 2004 |
Epstein-Barr virus positive large B-cell lymphoma arising in a patient previously treated with Cladribine for hairy cell leukemia.
Topics: Aged; Cladribine; Fatal Outcome; Herpesvirus 4, Human; Humans; Immunohistochemistry; Immunosuppressive Agents; Leukemia, Hairy Cell; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary | 2004 |
Successful treatment of extranodal Hodgkin's lymphoma in a patient with longstanding hairy cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Hodgkin Disease; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Pentostatin | 2005 |
Concomitant hairy cell and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Genetic Predisposition to Disease; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stem Cell Transplantation | 2006 |
The simultaneous occurrence of variant hairy cell leukemia and chronic-phase chronic myelogenous leukemia. A case report.
Topics: Aged; Aged, 80 and over; Cladribine; Humans; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Neoplasms, Second Primary; Splenectomy | 1995 |
Hairy cell leukemia: treatment results and association with secondary malignancy.
Topics: China; Cladribine; Humans; Interferon-alpha; Leukemia, Hairy Cell; Melanoma; Neoplasms, Second Primary | 1995 |
Secondary neoplasms in two patients treated with purine analogues.
Topics: Acute Disease; Aged; Cladribine; Female; Humans; Immunocompromised Host; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melanoma; Neoplasms, Second Primary; Skin Neoplasms; Vidarabine; Waldenstrom Macroglobulinemia | 1994 |
Second cancer risk in hairy cell leukemia: analysis of 350 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Pentostatin; Referral and Consultation; Survival Analysis | 1997 |
Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; British Columbia; Cladribine; Combined Modality Therapy; Comorbidity; Female; Humans; Immunologic Factors; Incidence; Interferons; Leukemia, Hairy Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Pentostatin; Prospective Studies; Risk; Smoking; Splenectomy | 1998 |
Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Interferons; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pentostatin; Remission Induction; Splenectomy; Survival Analysis; Treatment Failure | 1998 |
2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Cohort Studies; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasms, Second Primary; Neutropenia; Poland; Survival Rate; Thrombocytopenia; Time Factors; Treatment Outcome | 1999 |
Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias.
Topics: Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Pentostatin; Vidarabine | 1999 |
Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Marrow; CD4 Lymphocyte Count; Cladribine; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infections; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Second Primary; Opportunistic Infections; Pentostatin; Remission Induction; Splenectomy; Survival Rate | 1999 |
Secondary acute myeloid leukemia following successful treatment of hairy cell leukemia with cladribine.
Topics: Acute Disease; Aged; Antineoplastic Agents; Blood Cell Count; Cladribine; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid; Male; Neoplasms, Second Primary | 2000 |
Richter's syndrome following cladribine therapy for chronic lymphocytic leukemia first manifested as pathologic fracture of the femur.
Topics: Aged; Bone Marrow; Cell Transformation, Neoplastic; Cladribine; Femoral Fractures; Humans; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary; Radionuclide Imaging; Syndrome | 2001 |